Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.52)
# 2,292
Out of 5,141 analysts
140
Total ratings
55.68%
Success rate
-2.14%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAY Waystar Holding | Maintains: Outperform | $40 → $27 | $25.07 | +7.70% | 5 | Feb 18, 2026 | |
| HNGE Hinge Health | Maintains: Outperform | $65 → $50 | $41.31 | +21.04% | 3 | Feb 11, 2026 | |
| DGX Quest Diagnostics | Maintains: In-Line | $190 → $220 | $202.41 | +8.69% | 5 | Feb 11, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $180 → $200 | $190.02 | +5.25% | 16 | Feb 5, 2026 | |
| MDLN Medline | Initiates: Outperform | $50 | $49.80 | +0.40% | 1 | Jan 12, 2026 | |
| FTRE Fortrea Holdings | Upgrades: Outperform | $14 → $25 | $11.00 | +127.27% | 11 | Jan 6, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $28 → $30 | $21.99 | +36.43% | 5 | Nov 7, 2025 | |
| OMDA Omada Health | Maintains: Outperform | $27 → $28 | $11.62 | +140.96% | 1 | Nov 7, 2025 | |
| DOCS Doximity | Maintains: Outperform | $81 → $70 | $25.55 | +173.97% | 10 | Nov 7, 2025 | |
| HSIC Henry Schein | Maintains: Outperform | $83 → $90 | $79.57 | +13.11% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $220 | $224.44 | -1.98% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $9 → $8 | $4.74 | +68.78% | 6 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $76.69 | +23.88% | 10 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $17 → $13 | $12.54 | +3.67% | 8 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $220 → $240 | $165.62 | +44.91% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $1.79 | +67.60% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $305 | $282.67 | +7.90% | 7 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $800 → $825 | $947.48 | -12.93% | 7 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $29.12 | -21.02% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $0.44 | +585.56% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $1.63 | +1,515.38% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $1.48 | +913.51% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $0.89 | +1,135.96% | 2 | Jan 4, 2022 |
Waystar Holding
Feb 18, 2026
Maintains: Outperform
Price Target: $40 → $27
Current: $25.07
Upside: +7.70%
Hinge Health
Feb 11, 2026
Maintains: Outperform
Price Target: $65 → $50
Current: $41.31
Upside: +21.04%
Quest Diagnostics
Feb 11, 2026
Maintains: In-Line
Price Target: $190 → $220
Current: $202.41
Upside: +8.69%
Align Technology
Feb 5, 2026
Maintains: Outperform
Price Target: $180 → $200
Current: $190.02
Upside: +5.25%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $50
Current: $49.80
Upside: +0.40%
Fortrea Holdings
Jan 6, 2026
Upgrades: Outperform
Price Target: $14 → $25
Current: $11.00
Upside: +127.27%
Privia Health Group
Nov 7, 2025
Maintains: Outperform
Price Target: $28 → $30
Current: $21.99
Upside: +36.43%
Omada Health
Nov 7, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $11.62
Upside: +140.96%
Doximity
Nov 7, 2025
Maintains: Outperform
Price Target: $81 → $70
Current: $25.55
Upside: +173.97%
Henry Schein
Nov 5, 2025
Maintains: Outperform
Price Target: $83 → $90
Current: $79.57
Upside: +13.11%
Oct 31, 2025
Maintains: Outperform
Price Target: $190 → $220
Current: $224.44
Upside: -1.98%
Oct 30, 2025
Maintains: In-Line
Price Target: $9 → $8
Current: $4.74
Upside: +68.78%
Oct 30, 2025
Maintains: Outperform
Price Target: $85 → $95
Current: $76.69
Upside: +23.88%
Oct 8, 2025
Maintains: In-Line
Price Target: $17 → $13
Current: $12.54
Upside: +3.67%
Oct 8, 2025
Maintains: Outperform
Price Target: $220 → $240
Current: $165.62
Upside: +44.91%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $1.79
Upside: +67.60%
Oct 3, 2025
Maintains: Outperform
Price Target: $300 → $305
Current: $282.67
Upside: +7.90%
Sep 24, 2025
Maintains: Outperform
Price Target: $800 → $825
Current: $947.48
Upside: -12.93%
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $29.12
Upside: -21.02%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $0.44
Upside: +585.56%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $1.63
Upside: +1,515.38%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $1.48
Upside: +913.51%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $0.89
Upside: +1,135.96%